publication venue for
- Canadian bone marrow transplant group (CBMTG) will use modified perugia protocol for multi-centre pilot study of haplo-identical transplantation 2002
- Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease. 38:877-882. 2024
- Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study. 38:570-578. 2024
- Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. 38:502-512. 2024
- PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. 37:2367-2382. 2023
- Infection risk associated with clonal hematopoiesis of indeterminate potential is partly mediated by hematologic cancer transformation in the UK Biobank. 37:2306-2308. 2023
- Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. 35:2650-2657. 2021
- External validation of the FIRST trial’s simplified frailty score in a population-based cohort. 35:1823-1827. 2021
- Revised 15-item MDS-specific frailty scale maintains prognostic potential. 34:3434-3438. 2020
- ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. 34:1907-1923. 2020
- Simplified frailty assessment tools: are we really capturing frailty or something else?. 34:1967-1969. 2020
- An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. 34:1394-1406. 2020
- Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. 33:1541-1541. 2019
- LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. 33:1411-1426. 2019
- Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?. 32:2095-2104. 2018
- Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress. 32:285-294. 2018
- Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). 31:2523-2525. 2017
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. 31:2529-2531. 2017
- NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. 30:473-483. 2016
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. 29:526-534. 2015
- Functional role of BAALC in leukemogenesis. 26:532-536. 2012
- Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. 25:1232-1238. 2011
- Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). 24:320-334. 2010
- A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. 23:631-634. 2009
- Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials. 23:811-813. 2009
- Leukemia targeting ligands isolated from phage display peptide libraries. 21:411-420. 2007
- The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. 19:1161-1168. 2005
- Analysis of p73 expression pattern in acute myeloid leukemias: lack of ΔN-p73 expression is a frequent feature of acute promyelocytic leukemia. 18:1804-1809. 2004
- Coculture and transplant of purified CD34+Lin− and CD34−Lin− cells reveals functional interaction between repopulating hematopoietic stem cells. 17:1613-1625. 2003
- Differential response of primitive human CD34− and CD34+ hematopoietic cells to the Notch ligand Jagged-1. 17:1366-1374. 2003
- Reply to C Delfini et al. 16:2175-2175. 2002
- Workshop on haploidentical stem cell transplantation: Chicago, Illinois, USA, 18-19 November 2000. 16:424-426. 2002
- AC133 expression in human stem cells. 15:1685-1688. 2001
- Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study. 15:846-854. 2001
- Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995). 14:2247-2256. 2000
- PML/RARα APL with undifferentiated morphology and stem cell immunophenotype. 12:1492-1493. 1998
- Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies.. 10:1370-1376. 1996
- The arotinoids: early clinical experience and discussion of future development.. 8:1817-1824. 1994
- Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.. 8:1622-1625. 1994
- M-CSF and 1,25 dihydroxy vitamin D3 synergize with 12-O-tetradecanoylphorbol-13-acetate to induce macrophage differentiation in acute promyelocytic leukemia NB4 cells.. 8:1744-1749. 1994
- Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.. 8 Suppl 3:S38-S41. 1994
- The arotinoids: early clinical experience and discussion of future development.. 8 Suppl 3:S42-S49. 1994
- The isolation of the human delta chain gene and its expression in normal T cells and T cell leukemias.. 2:717-721. 1988
- Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines.. 2:371-376. 1988